Email
Print
Testicular Cancer Drugs Market - Forecast(2024 - 2030)
Testicular Cancer Drugs Market Overview
Testicular Cancer Drugs Market size is estimated to reach
$876.5 million by 2027 and it is poised to grow at a CAGR of 6.2% over
the forecast period of 2022-2027. Testicular Cancer refers to the type of rare
cancer in men which accounts for nearly 1% of all the cancers that occur in the
following gender. Testicular cancer is unusual compared to other forms of
cancer owing to its tendency to affect younger men, mostly diagnosed in men
between the ages of 15 to 49. The testicular cancer drugs market in the U.K. is
positively placed owing to a case diagnosis of nearly 2,300 men in the country.
Similarly, the testicular cancer drugs industry in the U.S. is positively
placed owing to technological and pharmaceutical development. Owing to robust
pharmaceutical growth in various regions along with growing cases of the following
cancer in younger men, the testicular cancer drugs industry is projected to
offer marketable opportunities in the forecast period of 2022-2027.
Testicular Cancer Drugs Market Report Coverage
The report: “Testicular Cancer Drugs Market Forecast
(2022-2027)" by IndustryARC, covers an in-depth analysis of the following
segments in the Testicular Cancer Drugs Market.
Key Takeaways
- Geographically, the testicular cancer drugs market in North America dominated in 2021. Moreover, the testicular cancer drugs industry in the U.S. has been registering growth in the previous years owing to the availability of pharmaceutical giants. However, the European region is expected to offer lucrative growth opportunities in the forecast period owing to the increasing incidence of the following cancer as per various research articles.
- The rising incidence of testicular cancer in the white-male-dominated region along with the overwhelming growth in the pharmaceutical industry pertinent to cancer ailment and ramification will drive the market. However, factors limiting the growth include associated side effects of the treatment options and lack of diagnosis in earlier stages of cancer.
- A detailed analysis of the strengths, weaknesses, opportunities and threats will be provided in the Testicular Cancer Drugs Market Report.
Testicular Cancer Drugs Market - by Types of Cancer
Testicular Cancer Drugs Market based on the type of cancer
can be segmented into Seminoma (Classical, Spermatocytic); Non-Seminoma
(Embryonal Carcinoma, Yolk Sac Carcinoma, Choriocarcinoma, Teratoma) and
Stromal Tumors. Seminoma form of testicular cancer held a dominant market share
in the year 2021. As per Cancer Research UK, the following form of testicular
cancer accounts for nearly 40-50% of all the prevalent testis cancer. Seminomas
tend to grow and spread more slowly than non-Seminoma. However, the Non-Seminoma
form of testicular cancer is estimated to be the fastest-growing, with a CAGR
of 7.6% over the forecast period of 2022-2027. It is owing to rising cases of
the following form of cancer coming into observation. Critically, the following
form of cancer represents mixed germ cell testicular malignancies.
Testicular Cancer Drugs Market - by Sales Channel
Testicular Cancer Drugs market based on Sales channels can
be further segmented into Hospital Pharmacies, Drug stores & Retail Pharmacies and Online Pharmacies and Others. Hospital Pharmacies held a dominant market
share in the year 2021. It is owing to a significant number of chemotherapy
services performed in the following set-up. Stage-II and Stage-III prognosis of
testicular cancer must be treated with chemotherapy along with surgery. Moreover,
hospital pharmacies are estimated to be the fastest-growing, with a CAGR of 7.9%
over the forecast period of 2022-2027. Owing to a considerable rise in both
seminoma and non-seminoma along with chemotherapy as a proven methodology,
hospital pharmacies will continue to grow and hold a sizable share of the
market. As per CDC, nearly 650,000 cancer patients receive chemotherapy from outpatient
oncology clinics.
Testicular Cancer Drugs Market - by Geography
Testicular Cancer Drugs Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. The testicular cancer drugs market in North America held a dominant market share of 37% in 2021. It is primarily owing to the testicular cancer drugs industry in the U.S., which has been growing at a considerable pace owing to the presence of robust healthcare infrastructure and patient awareness pertinent to cancer and treatment. However, Europe is estimated to be the fastest-growing region with a CAGR over the forecast period of 2022-2027. As per the Science Direct estimation model, testicular cancer incidence is expected to rise by 25% in Europe by 2025. As per the analysis, within Europe, nearly 23,000 new cases will be diagnosed with testicular cancer, a rise of 24% from 2005 levels.
Testicular Cancer Drugs Market Drivers
Growing Incidence and Prevalence of Testicular Cancer Across the Globe are Aiding the Market Growth.
As per John Hopkins Medicine, it is estimated that nearly
8,000-10,000 men develop following cancer each year. Moreover, the incidence of
testicular cancer is about 1:270 across the globe. Testis cancer has been
underlined to be highly prevalent in men in their late 20s or early 30s with an
average age of diagnosis to be 33 years old. Owing to the genetic makeup of white
men, the prevalence of testicular cancer is higher by nearly 4-5 times than
black or Hispanic or Latino or Asian- Americans. Coincidentally, as per
Visualist Capitalist 2019 data, around 2.3 billion or 29.9% of the global
population is between 20-39, with estimations suggesting a considerable rise in
the coming period will positively augment the market growth.
The surge of Pharmaceutical Technology along with a General Increase in the Research and Development Activities Pertaining to Cancer Treatment has been a Market Propeller.
Pharmaceutical research and spending have been growing at a
robust pace which continues to benefit the overall testicular cancer treatment
market. For example, BioNTech represented an encouraging phase ½ follow-up data
for CAR-T Candidate BNT 211 in Hard-To-Treat Solid tumors at RSMO. Major cancer
research bodies are noticing an increase in their R&D budgets. For example,
as per analysis for funding received by the National Cancer Institute, the
research budget grew from $4.9 billion in 2016 to $6.4 billion in 2020
registering a percentage increase of 30% in five years.
Testicular Cancer Drugs Market Challenges
Lower Awareness of Testicular Cancer along with Drug Side Effects Impedes the Overall Market Growth.
The awareness pertinent to testicular cancer remains highly
negligible owing to various societal constructs. Some of the critical analysis
based on the MDU study highlights three critical reasons for delays in testicular
cancer diagnosis and treatment. Initially, patients diagnosed with testicular
cancer commonly alleged there had been a delayed referral after they found a
lump or other abnormality of the testis. The overwhelming majority of the cases
alleged a delayed diagnosis of prostate cancer (81%), with the other 19%
alleging delayed diagnosis of testicular cancer in male cancers.
Testicular Cancer Drugs Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Testicular
Cancer Drugs market. The top 10 companies in the Testicular Cancer Drugs market are:
- Bristol-Myers Squibb Company
- Fresenious Kabi AG
- Teva Pharmaceuticals
- Pfizer Inc.
- H. Lundbeck A/S
- Ziopharm Oncology
- BioNTech SE
- Baxter International Inc.
- Hospira Inc.
- Ovation Pharmaceuticals
Recent Developments
- In September 2022, the 2022 European Society for Medical Oncology Congress showed the cut-off for 21 patients expressed positive results for investigational CAR-T cell therapy, BNT211-01, which showed promise in treating patients with CLDN6-positive, relapsed/refractory solid cancers such as testicular cancer.
- In July 2022, Bleomycin- a common form of antibiotic used as a chemotherapy agent for testicular cancer treatment induced lung injury in the latest research. Additionally, lung injury is often proven to be fatal. Iron binds to a structural component of bleomycin and the compound it creates releases free radicals which promote cell death.
- In December 2020, a trial led by the Institute of Cancer Research, London and University Hospitals Birmingham NHS Foundation Trust involving 250 men with early-stage testicular cancer revealed that half the amount of chemotherapy prevents testicular cancer from coming back, following a combination of BEP.
Relevant Titles
Report Code- HCR 0965
Report Code- HCR 0197
Report Code- HCR 0078
For more Lifesciences and Healthcare Market reports, please click here